initiative  OCTALFA’s mission is two fold: facilitate innovation in healthcare and provide support to vulnerable people.

Initiative  OCTALFA works to bring about innovation in healthcare by incubating innovative startups in France.

Initiative  OCTALFA also supports projects aimed at improving quality of life for cancer patients and disabled people in France and Madagascar.


OCTALFA creates, funds and manages young innovative companies
OTONNALE identify innovative projects until they mature into fledgling companies
The corporate foundation Fondation Dominique & Tom Alberici – OCTALFA supports charity and non-profit projects addressing the challenges surrounding cancer and disabilities in France and Madagascar
The endowment fund Institut Dominique & Tom Alberici raises additional funds for projects supported by our corporate foundation


  • Gilles Alberici

    Gilles has 30 years of experience in the pharmaceutical and biotechnology sectors. He created and developedOPi, Pharmaceuticals for Rare Diseases and has taken more than ten products through clinical trials.

  • Julien Alberici
    Managing Director

    Julien is a graduate of EMLYON Business School and iaelyon management school. He has worked as a consultant in innovation management, business development andfinancial analysis,and is currently the Chief Executive Officer and co-founder ofMathym.

  • Jeremy Bastid
    R&D Director

    Jeremy is a pharmacist and oncologist, who specialises in immuno-oncology. He joined initiative OCTALFA in 2010 and manages OREGA Biotech as Chief Operating Officer.

  • Charlotte Maddalena
    Executive Assistant

    Charlotte Maddalena joined initiative OCTALFA in October 2016 as an executive assistant. Charlotte is also responsible for the administrative management of the Foundation’s projects.

  • Laurence Simon
    Administrative and Financial Director

    Laurence Simon is Administrative and Financial Director. She has more than 15 years of experience in the biotechnology sector where she worked for OPI, Eusa Pharma and Jazz Pharmaceuticals as Financial Director. She joined the initiative Octalfa team on November 3, 2016.


Formed in 2006, OCTALFA is the fruit of previous work carried out by Gilles Alberici, in particular during his time at OPi, a company that develops drugs for orphan diseases.

OCTALFA began by helping established innovative companies with financing operations. It founded and/or invested in 14 companies in France. Since 2016, OCTALFA concentrates its efforts to the development and management of its subsidiaries.

OTONNALE identify innovative industrial or academic projects before the inception of a company dedicated to their management.

Spearheaded by Dominique Alberici, OCTALFA created the OCTALFA Corporate Foundation in 2008 to provide help for cancer patients and disabled people. The corporate foundation was named Fondation Dominique & Tom Alberici – OCTALFA in 2011, following the passing away of Tom, Dominique and Gilles’ son.

Founded in 2012, the endowment fund Institut Dominique & Tom Alberici complements the corporate foundation’s activities by supporting charity projects that require both a more hands-on approach and additional funding. This funding is provided by OCTALFA and our donors.



    Strengthens its capital base and accelerates its development

  • Merry Christmas and Happy New year 2018

    initiative OCTALFA wishes you a Merry Christmas and a Happy New Year 2018

  • Millendo Therapeutics acquires Alizé Pharma

    The clinical-stage company focused on novel treatments for endocrine diseases will develop Alizé’s livoletide (AZP-531) for PWS.

  • December 2017 newsletter

    Read the newsletter of the endowment fund Institut Dominique & Tom Alberici

  • Mathym launches filyxio®, a radiopacifying nano-dispersion made from ytterbium trifluoride (YbF3)

    Mathym SAS, a company specialized in the development, manufacturing and commercialization of nano-dispersions dedicated to biomedical applications, announces today the complete implementation of its first manufacturing line and the beginning of commercialization of filyxio®.

  • SIOP 2017

    Jeremy Bastid will attend the SIOP (Société Internationale d’Oncologie Pédiatrique) Congress in Washington, october 12-15.

  • Meet us at Bio Europe 2017 in Berlin

    Jeremy Bastid will attend the Bio-Europe event to be held in Berlin (Germany), november 6-8.

  • One project supported by our Endowment Fund

    On 7th of July 2017, the foundation decided to support, throught its endowment fund Institut Dominique & Tom Alberici, Orchidées Blanches, center for disabled people in Madagascar, for the replacement of the pickup bus for its residents.